Drug intelligence / Profile preview

Target Y modulator

Development stage: Preclinical
Lead developer: Golgi Neurosciences
Modality: Small Molecules

Overview

Target Y modulator is a preclinical small molecule drug candidate being developed by Golgi Neurosciences, an Italian biotechnology company-creator. The program is currently focused on the treatment of amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Golgi Neurosciences operates by identifying and validating novel therapeutic targets for neurodegenerative diseases and then advancing them through early development. As of the current reporting, the specific identity of 'Target Y' and the exact mechanism of action remain proprietary and have not been publicly disclosed.

Beyond the preview

Go deeper on Target Y modulator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Target Y modulator.

Explore the full profile